Genfit is a biopharmaceutical company that specialises in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is developing treatments for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver or the bowel. Genfit’s drug pipeline includes treatments for NASH and Primary biliary cholangitis, as well as diagnostic tests for these diseases.